Editas Medicine (EDIT) Tops Q4 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts EDIT Hot Sheet
Join SI Premium – FREE
Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.23), $0.36 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $60.04 million versus the consensus estimate of $3.7 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Janus Living, Inc. (JAN) Reports Q3 Loss of $0.02 ; Offers Guidance
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
